N-Isoxazolyl Biphenylsulfonamides
J ournal of Medicinal Chemistry, 2002, Vol. 45, No. 18 3835
(10) Massart, P. E.; Hodeige, D. G.; Van Mechelen, H.; Charlier, A.
A.; Ketelslegers, J . M.; Heyndrickx, G. R.; Donckier, J . E.
Angiotensin II and endothelin-1 receptor antagonists have
cumulative hypotensive effects in canine Page hypertension. J .
Hypertens. 1998, 16, 835-841.
(11) Bohlender, J .; Gerbaulet, S.; Kramer, J .; Gross, M.; Kirchengast,
M.; Dietz, R. Synergistic effects of AT(1) and ET(A) receptor
blockade in a transgenic, angiotensin II-dependent, rat model.
Hypertension 2000, 35, 992-997.
(12) Walsh, T. F.; Fitch, K. J .; Williams, D. L., J r.; Murphy, K. L.;
Nolan, N. A.; Pettibone, D. J .; Chang, R. S. L.; O’Malley, S. S.;
Clineschmidt, B. V.; Veber, D. F.; Greenlee, W. J . Potent dual
antagonists of endothelin and angiotensin II receptors derived
from R-phenoxyphenylacetic acids. Part III. Bioorg. Med. Chem.
Lett. 1995, 5, 1155-1158.
(13) Dascal, D.; Nirula, V.; Lawus, K.; Yoo, S.; Walsh, T. F.; Sandberg,
K. Shared determinants of receptor binding for subtype selective,
and dual endothelin-angiotensin antagonists on the AT1 angio-
tensin II receptor. FEBS Lett. 1998, 423, 15-20.
(14) Murugesan, N.; Gu, Z.; Stein, P. D.; Bisaha, S.; Spergel, S.;
Girotra, R.; Lee, V. G.; Lloyd, J .; Misra, R. N.; Schmidt, J .;
Mathur, A.; Stratton, L.; Kelly, Y. F.; Bird, E.; Waldron, T.; Liu,
E. C. K.; Zhang, R.; Lee, H.; Serafino, R.; Abboa-Offei, B.;
Mathers, P.; Giancarli, M.; Seymour, A. A.; Webb, M. L.;
Moreland, S.; Barrish, J . C.; Hunt, J . T. Biphenylsulfonamide
Endothelin Antagonists: Structure-Activity Relationships of a
Series of Mono- and Disubstituted Analogs and Pharmacology
of the Orally Active Endothelin Antagonist 2′-Amino-N-(3,4-
dimethyl-5-isoxazolyl)-4′-(2-methylpropyl)[1,1′-biphenyl]-2-sul-
fonamide (BMS-187308). J . Med. Chem. 1998, 41, 5198-
5218.
(15) Murugesan, N.; Gu, Z.; Stein, P. D.; Spergel, S.; Mathur, A.;
Leith, L.; Liu, E. C. K.; Zhang, R.; Bird, E.; Waldron, T.; Marino,
A.; Morrison, R. A.; Webb, M. L.; Moreland, S.; Barrish, J . C.
Biphenylsulfonamide endothelin receptor antagonists. 2. Dis-
covery of 4′-oxazolyl biphenylsulfonamides as a new class of
potent, highly selective ETA antagonists. J . Med. Chem. 2000,
43, 3111-3117.
(16) Murugesan, N.; Gu, Z.; Stein, P. D.; Bisaha, S.; Spergel, S.; Liu,
E. C. K.; Zhang, R.; Webb, M. L.; Moreland, S.; Barrish, J . C.
Biphenylsulfonamide Endothelin Receptor Antagonists. 3. Struc-
ture-Activity Relationship of 4′-Heterocyclic Biphenylsulfon-
amides. Bioorg. Med. Chem. Lett. 2002, 12, 517-520.
(17) Murugesan, N.; Gu, Z.; Spergel, S.; Young, M.; Chen, P.; Liu, E.
C. K.; Zhang, R.; Bird, E.; Waldron, T.; Marino, A.; Koplowitz,
B.; Griffith, W.; Chong, S.; Morrison, R. A.; Webb, M. L.;
Moreland, S.; Barrish, J . C. Biphenylsulfonamide endothelin
receptor antagonists. 4. Discovery of BMS-207940, a highly
potent and orally active ETA selective antagonist. Manuscript
in preparation.
(18) Dickinson, K. E. J .; Cohen, R. B.; Skwish, S.; Delaney, C. L.;
Serafino, R. P.; Poss, M. A.; Gu, Z.; Ryono, D. E.; Moreland, S.;
Powell, J . R. BMS-180560, an insurmountable inhibitor of
angiotensin II-stimulated responses: comparison with losartan
and EXP3174. Br. J . Pharmacol. 1994, 113, 179-189.
(19) Christophe, B.; Libon, R.; Cazaubon, C.; Nisato, D.; Manning,
A.; Chatelain, P. Effects of irbesartan on angiotensin II-induced
pressor responses in the pithed rat: potential mechanisms of
action. Eur. J . Pharmacol. 1995, 281, 161-171.
µmol/kg) dosed orally also significantly decreased the Ang II
pressor response over 4 h. The difference between the maxi-
mum blood pressure increase before and after the drug was
reported as the percent inhibition of the Ang II pressor effect.
b. En d oth elin . This study was performed as previously
described.15 Intravenous injection of big endothelin-1 (bET-1,
1.0 nmol/kg) into conscious normotensive rats causes a gradual
and sustained increase in blood pressure that is inhibited by
ETA receptor antagonists. The initial ET-1 challenge was
preceded by vehicle administration to establish a control
response to the agonist. Compounds 2 (3 and 30 µmol/kg) and
15 (10 and 30 µmol/kg) were administered after control ET-1
pressor response and at 15, 105, and 195 min intervals after
drug dosing ET-1 was injected iv.
Refer en ces
(1) (a) Moser, M. Is it time for
a new approach to the initial
treatment of hypertension? Arch. Intern. Med. 2001, 161, 1140-
1144. (b) Sever, P. The heterogeneity of hypertension: why does
not every patient respond to every antihypertensive drug? J .
Cardiovasc. Pharmacol. 1998, 31 (Suppl. 2), S1-S4. (c) Coca A.
Actual blood pressure control: are we doing things right? J .
Hypertens. 1998, 16, S45-S51.
(2) (a) Waeber, B. Achieving blood pressure targets in the manage-
ment of hypertension. Blood Pressure, Suppl. 2001, 2, 6-12. (b)
Gavras, H. P. Issues in hypertension: drug tolerability and
special populations. Am. J . Hypertens. 2001, 14 (Part 2), 231S-
236S.
(3) (a) Yanagisawa, M.; Kurihara, H.; Kimura, S.; Tomobe, Y.;
Kobayashi, M.; Mitsui, Y.; Yazaki, Y.; Goto, K.; Masaki, T. A
novel potent vasoconstrictor peptide produced by vascular endo-
thelial cells. Nature (London) 1988, 332, 411-415. (b) Inoue, A.;
Yanagisawa, M.; Kimura, S.; Kasuya, Y.; Miyauchi, T.; Goto, K.;
Masaki, T. The human endothelin family: three structurally and
pharmacologically distinct isopeptides predicted by three sepa-
rate genes. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 2863-2867.
(c) Ferrario, C. M. The Renin-Angiotensin System: Importance
in Physiology and Pathology. J . Cardiovasc. Pharmacol. 1990,
15 (Suppl. 3), S1-S5.
(4) (a) Burnier, M. Angiotensin II type 1 receptor blockers. Circula-
tion 2001, 103, 904-912. (b) Ashton, W. T. Nonpeptide Angio-
tensin II Receptor Antagonists. Expert Opin. Invest. Drugs 1994,
3, 1105-1142. (c) Wexler, R. R.; Greenlee, W. J .; Irvin, J . D.;
Goldberg, M. R.; Prendergast, K.; Smith, R. D.; Timmermans,
P. B. M. W. M. Nonpeptide Angiotensin II Receptor Antago-
nists: The Next Generation in Antihypertensive Therapy. J .
Med. Chem. 1996, 39, 625-656.
(5) (a) Sakurai, T.; Yanagisawa, M.; Masaki, T. Molecular Charac-
terization of Endothelin Receptors. Trends Pharmacol. Sci. 1992,
13, 103-108. (b) Masaki, T.; Vane, J . R.; Vanhoutte, P. M. V.
International Union of Pharmacology. Nomenclature of Endo-
thelin Receptors. Pharmacol. Rev. 1994, 46, 137-142. (c) Arai,
H.; Hori, S.; Aramori, I.; Ohkubo, H.; Nakanashi, S. Cloning and
Expression of a cDNA Encoding an Endothelin Receptor. Nature
1990, 348, 730-732. (d) Sakurai, T.; Yanagisawa, M.; Takuwa,
Y.; Miyazaki, H.; Kimura, S.; Goto, K.; Masaki, T. Cloning of a
cDNA Encoding
a Non-Isopeptide-Selective Subtype of the
Endothelin Receptor. Nature 1990, 348, 732-735.
(6) (a) Elliott, J . D.; Ohlstein, E. H.; Peishoff, C. E.; Ellens, H. M.;
Lago, M. A. Endothelin receptor antagonists. Pharm. Biotechnol.
1998, 11, 113-129. (b) Spieker, L. E.; Noll, G.; Ruschitzka, F.
T.; Luscher, T. F. Endothelin receptor antagonists in congestive
heart failure: A new therapeutic principle for the future? J . Am.
Coll. Cardiol. 2001, 37, 1493-1505.
(7) Dao, H. H.; Moreau, P. An update on the status of endothelin
receptor antagonists for hypertension. Expert Opin. Invest. Drugs
2001, 10, 1937-1946.
(8) Ikeda, T.; Ohta, H.; Okada, M.; Kawai, N.; Nakao, R.; Siegl, P.
K. S.; Kobayashi, T.; Miyauchi, T.; Nishikibe, M. Antihyperten-
sive effects of a mixed endothelin-A- and -B-receptor antagonist,
J -104132, were augmented in the presence of an AT1-receptor
antagonist, MK-954. J . Cardiovasc. Pharmacol. 2000, 36 (Suppl.
1), S337-S341.
(9) Gardiner, S. M.; March, J . E.; Kemp, P. A.; Mullins, J . J .;
Bennett, T. Hemodynamic effects of losartan and the endothelin
antagonist, SB 209670, in conscious, transgenic ((mRen-2)27),
hypertensive rats. Br. J . Pharmacol. 1995, 116, 2237-2244.
(20) Bird, J . E.; Moreland, S.; Waldron, T. L.; Powell, J . R. Antihy-
pertensive effects of a novel endothelin-A receptor antagonist
in rats. Hypertension (Dallas) 1995, 25, 1191-1195.
(21) Bernhart, C. A.; Perreaut, P. M.; Ferrari, B. P.; Muneaux, Y.
A.; Assens, J . L. A.; Clement, J .; Haudricourt, F.; Muneaux, C.
F.; Taillades, J . E. A new series of imidazolones: highly specific
and potent nonpeptide AT1 angiotensin II receptor antagonists.
J . Med. Chem. 1993, 36, 3371-3380.
(22) Zhang, H. Y.; Yu, J . Q.; Bruice, T. C. Synthesis of a spheroidal
bis-porphyrin: a ligand designed to accept two catalytic metal
ions in an isolated environment. Tetrahedron 1994, 50, 11339-
11362.
(23) Scheinmann, F.; Stachulski, A. V. Convenient synthesis of a
novel γ-aminobutyric acid analog: 4-amino-2,2-dimethylbutanoic
acid. J . Chem. Res., Synop. 1993, 10, 414-415.
J M020138N